Journal of Sulfur Chemistry 381
21.59. MS (m/z, %): 321 (M+, 11). 1H NMR (400 MHz, DMSO-d6): δ 2.43 (3H, s, CH3), 7.83
3
3
(2H, d, JHH = 8.4 Hz, 2CH of C6H4Cl), 8.11 (2H, d, JHH = 8.4 Hz, 2CH of C6H4Cl), 13.77
(1H, s, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 17.4 (CH3), 128.7, 129.9, 134.1, and 139.1
=
(aryl moiety), 148.1 (C), 148.5 (C), 151.6 (C), 161.8 and 168.6 (2C O) ppm.
3.1.5. N-(3-methyl 4-oxo-4H-[1,3,4]thiadiazolo[2,3-c][1,2,4]triazin-7-yl)
4-bromobenzamide (4e)
White powder; m.p. > 300 ◦C, IR (KBr) (νmax cm−1): 3250, 2980, 1707, 1665, 1589, 1556, 1376.
Analyses: Calcd for C12H8BrN5O2S: C, 39.36; H, 2.20; N, 19.12%. Found: C, 39.20; H, 2.14;
N, 19.26. MS (m/z, %): 366 (M+, 5). 1H NMR (400 MHz, DMSO-d6): δ 2.43 (3H, s, CH3), 7.93
3
3
(2H, d, JHH = 8.4 Hz, 2CH of C6H4Br), 8.06 (2H, d, JHH = 8.4 Hz, 2CH of C6H4Br), 13.76
(1H, s, NH) ppm. 13C NMR (100 MHz, DMSO-d6): δ 17.4 (CH3), 126.7, 129.8, 132.1, and 136.1
=
(aryl moiety), 148.2 (C), 148.6 (C), 151.5 (C), 161.8 and 168.7 (2C O) ppm.
3.1.6. N-(3-methyl 4-oxo-4H-[1,3,4]thiadiazolo[2,3-c][1,2,4]triazin-7-yl)
3-nitrobenzamide (4f)
White powder; m.p. > 310 ◦C, IR (KBr) (νmax cm−1): 3230, 1697, 1675, 1596, 1524, 1497, 1457,
1378. Analyses: Calcd for C12H8N6O4S: C, 43.37; H, 2.43; N, 25.29%. Found: C, 43.51; H, 2.30;
N, 25.48. MS (m/z, %): 332 (M+, 9). 1H NMR (400 MHz, DMSO-d6): δ 2.43 (3H, s, CH3), 7.76
(2H, t, 3JHH = 7.6 Hz, 2CH of C6H4NO2), 8.32 (1H, d, 3JHH = 8.0 Hz, 1CH of C6H4NO2), 8.51
(2H, d, 3JHH = 7.6 Hz, 2CH of C6H4NO2), 8.89 (1H, s, 1CH of C6H4NO2), 13.76 (1H, s, NH)
ppm. 13C NMR (100 MHz, DMSO-d6): δ 17.6 (CH3), 123.2, 125.7, 130.2, 134.9, 140.0, and 148.2
=
(aryl moiety), 148.4 (C), 151.1 (C), 153.8 (C), 161.9 and 169.1 (2C O) ppm.
Acknowledgement
We gratefully acknowledge financial support from the Research Council of Islamic Azad University of Yazd of Iran.
References
(1) El-Gendy, Z.; Morsy, J.M.; Allimony, H.A.; Abdel-Monem, A.R.; Abdel-Rahman, R.M. Pharmazie 2001, 56, 376–
384.
(2) Sztanke, K.; Pasternak, K.; Sztanke, M.; Kandefer-Szerszen´, M.; Kozioł, A.E.; Dybała, I. Bioorg. Med. Chem. Lett.
2009, 19, 5095–5100.
(3) Abdel-Rahman, R.M.; Seada, M.; Fawzy, M.; el Baz, I. Boll. Chim. Farm. 1994, 133, 381–388.
(4) Rusinov, V.L.; Chupakhin, O.N.; Deev, S.L.; Shestakova, T.S.; Ulomskii, E.N.; Rusinova, L.I.; Kiselev, O.I.; Deeva,
E.G. Russ. Chem. Bull. 2010, 59, 136–143.
(5) Louis, C.K.; Gurdip, S.B.; Jesse, L.; Khizar, W.; Madeleine, M.J.J. Med. Chem. 1976, 19, 845–852.
(6) Holla, B.S.; Sarojini, B.K.; Gonsalves, R. Farmaco 1998, 53, 395–398.
(7) Davidson, W.M.; Boykin, W.D. J. Pharm. Sci. 1978, 65, 737–376.
(8) Pustoshnaya, L.S.; Pustoshnyi, V.P.; Mazitova, A.K.; Khamaev, V.K.; Davydov, E.Y.; Zaikov, G.E.; Minsker, K.S.
Polym. Degrad. Stab. 2000, 70, 39–41.
(9) Oettmeier, W.; Hilp, U. J. Pestic. Sci. 1991, 33, 399–409.
(10) Olmeda, C.; Deban, L.; Barrado, E.; Castrillejo, Y.; Herrero, L. Electrochim. Acta 1994, 39, 2237–2241.
(11) Kang-Chieu, L.; Bi-Jane, S.; Chuen-Hsiang, L. J. Heterocycl. Chem. 1992, 29, 97–101.
(12) Onar, M.; Omaima, M.E.; Aboulwafa, M. J. Heterocycl. Chem. 1986, 23, 1339–1341.
(13) Bartlett, R.R.; Gebert, U.; Kerekjarto, V.; Schleyerbach, R.; Thorwart, W.; Weithmann, K.U. Drugs Exp. Clin. Res.
1989, 15, 521–526.
(14) Mizutani, M.; Sanemitsu, Y. Tetrahedron Lett. 1985, 26, 1237–1240.
(15) El-Shehawy, A.A. Tetrahedron Asymmetry 2006, 17, 2617–2624.
(16) Coppo, F.T.; Fawzi, M. J. Heterocycl. Chem. 1997, 34, 1351–1354.
(17) Mohebat, R.; Mosslemin, M.H.; Dehghan-Darehshiri, A.; Hassanabadi, A. J. Sulfur. Chem. 2011, 32, 557–561.